Metformin for olanzapine-induced weight gain in schizophrenia:a systematic review

Huizhi Zhou,Chen Yang,Shaohua Wang,Runxu Yang,Weihua Yue,Chuanyuan Kang

DOI: https://doi.org/10.3760/cma.j.issn.1006-7884.2017.01.018

2017-01-01

Abstract:Objective To undertake a systematic review to evaluate the efficacy of metformin on reducing weight gain in schizophrenics taking olanzapine. Methods Articles published before December 31, 2015 were identified by searching the Cochrane Library,PubMed, excerpta medica database(EMBASE), Ovid/Medline,PsycINFO, ISI web of knowledge, SinoMed, China national knowledge infrastructure (CNKI), WanFang data, and VIP Periodical, using the key words metformin, olanzapine, schizophren* and schizophrenia. Statistical analysis were conducted by Review Manager 5.3 software according to Cochrane Handbook for meta analysis. Results A total of 12 articles and 11 studies were identified. It was impossible to pool the data for meta-analytic purposes due to varieties of timing of initiating metformin treatment and different experimental designs. Therefore, targeted studies were divided into two groups for analyses(olanzapine+metformin group (metformin group), olanzapine monotherapy or olanzapine+placebo (control group)). The 5 studies in which metformin treatment was started at the same time as olanzapine:body weight and BMI were both increased in metformin group and control group. However, body weight (mean difference(MD):-3.59, 95%CI-6.62--0.57,P=0.02) and BMI(MD:-1.17,95%CI-2.05--0.29, P=0.009)in metformin group were both lower compared with those of control group at endpoint. The 6 studies in which metformin was added to a regimen after 3 months stable olanzapine treatment or when≥7%weight gain occurred. After adding metformin, body weight and BMI were statistically reduced compared with baseline(Z=2.86,P=0.004;Z=3.25,P=0.001).Compared with control group, metformin group showed lower body weight and BMI, but only difference in body weight between two groups was statistically significant (MD:-4.30,95%CI-7.19--1.40,P=0.004). Conclusion Metformin may have some value in preventing or reducing weight gain during treatment with olanzapine in schizophrenia.